| Biomarker ID | 1887 |
| PMID | 30623593 |
| Year | 2018 |
| Biomarker | Ig heavy chain Vâ€III region BRO; Alphaâ€1â€antitrypsin; Plasminogen (0.1†fold); Ig heavy chain Vâ€III region TIL, Hemopexin; Afamin; Interâ€alphaâ€trypsin inhibitor heavy chain H1; Protein AMBP; Alphaâ€1Bâ€glycoprotein; Complement component C8 alpha chain; |
| Biomarker Basis | Concentration Based |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | Upregulated in PCa [Alphaâ€1â€acid glycoprotein 1 (13.6â€fold); Alphaâ€1Bâ€glycoprotein (11.6â€fold); von Willebrand factor (5.0â€fold); Ig heavy chain Vâ€II region NEWM (6.0â€fold); Ig heavy chain Vâ€III region BRO (5.7â€fold); Afamin (5.4â€fold); Apolipoprotein Aâ€I (4.9â€fold); Isoform 3 of Vitamin Dâ€binding protein (4.3â€fold); Complement C1r subcomponent (4.3†fold); Angiotensinogen (4.1â€fold); |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | African American men with PCa (PAA) Vs Caucasian men with PCa (PCC) |
| Type of Biomarker | Diagnostic |
| Cohort | Serum samples from African American and Caucasian PCa patients and matched healthy donors were collected after patients’ consents |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.05 |
| Method Used | mass spectrometry |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |